Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

The influence of bolus to infusion delays on plasma Tissue Plasminogen Activator levels.

Smith C, Al-Nuaimi Y, Wainwright J, Sherrington C, Singh A, Kallingal J, Douglass C, Parry-Jones A, Smith C, Dixit A, Majid A.

Int J Stroke. 2014 Oct;9(7):939-42. doi: 10.1111/j.1747-4949.2012.00924.x. Epub 2012 Dec 4.

PMID:
23205632
2.

How to manage thrombolysis interruptions in acute stroke?

Brodoehl S, G√ľnther A, Witte OW, Klingner CM.

Clin Neuropharmacol. 2015 May-Jun;38(3):85-8. doi: 10.1097/WNF.0000000000000081.

PMID:
25970276
3.

Optimal thrombolytic strategies for acute myocardial infarction--bolus administration.

McMechan SR, Adgey AA.

QJM. 1998 Nov;91(11):719-25. Review.

PMID:
10024933
4.
5.
6.

Current status of intravenous thrombolysis for acute ischemic stroke in Asia.

Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, Srivastava PM, Sergentanis T, Suwanwela N, Nguyen TH, Lawrence Wong KS, Chan BP.

Int J Stroke. 2011 Dec;6(6):523-30. doi: 10.1111/j.1747-4949.2011.00671.x. Review.

PMID:
22111797
7.

Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).

Eissa A, Krass I, Bajorek BV.

J Clin Pharm Ther. 2012 Dec;37(6):620-9. doi: 10.1111/j.1365-2710.2012.01366.x. Epub 2012 Jun 19. Review.

PMID:
22708668
8.

Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers.

Hargis M, Shah JN, Mazabob J, Rao CV, Suarez JI, Bershad EM.

Clin Neurol Neurosurg. 2015 Aug;135:79-84. doi: 10.1016/j.clineuro.2015.04.027. Epub 2015 May 22.

PMID:
26047090
9.

Bolus fibrinolytic therapy in acute myocardial infarction.

Llevadot J, Giugliano RP, Antman EM.

JAMA. 2001 Jul 25;286(4):442-9. Review.

PMID:
11466123
10.

Role of tissue plasminogen activator in acute ischemic stroke.

Hatcher MA, Starr JA.

Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Review.

PMID:
21386027
12.
13.

Thrombolysis for acute ischaemic stroke.

Wardlaw JM, Zoppo G, Yamaguchi T, Berge E.

Cochrane Database Syst Rev. 2003;(3):CD000213. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD000213.

PMID:
12917889
14.

Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.

Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team..

Arch Neurol. 2004 Mar;61(3):346-50.

PMID:
15023810
15.

Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator.

Sharma VK, Kawnayn G, Sarkar N.

Expert Rev Neurother. 2013 Aug;13(8):895-902. doi: 10.1586/14737175.2013.827412. Review.

PMID:
23965163
16.

Does a 'code stroke' rapid access protocol decrease door-to-needle time for thrombolysis?

Tai YJ, Weir L, Hand P, Davis S, Yan B.

Intern Med J. 2012 Dec;42(12):1316-24. doi: 10.1111/j.1445-5994.2011.02709.x.

PMID:
22212180
17.

Early insulin glycemic control combined with tPA thrombolysis reduces acute brain tissue damages in a focal embolic stroke model of diabetic rats.

Fan X, Ning M, Lo EH, Wang X.

Stroke. 2013 Jan;44(1):255-9. doi: 10.1161/STROKEAHA.112.663476. Epub 2012 Nov 1.

18.

Reducing in-hospital delay to 20 minutes in stroke thrombolysis.

Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M.

Neurology. 2012 Jul 24;79(4):306-13. doi: 10.1212/WNL.0b013e31825d6011. Epub 2012 May 23.

PMID:
22622858
19.
20.

Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.

Uchino K, Alexandrov AV, Garami Z, El-Mitwalli A, Morgenstern LB, Grotta JC.

Cerebrovasc Dis. 2005;19(4):260-6. Epub 2005 Feb 22.

PMID:
15731557

Supplemental Content

Support Center